Production (Stage)
BioXcel Therapeutics, Inc.
BTAI
$1.39
$0.021.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 73.82% | 66.71% | 66.45% | 46.86% | 18.19% |
| Total Depreciation and Amortization | -2.85% | -2.83% | -3.43% | -4.59% | -4.24% |
| Total Amortization of Deferred Charges | -28.53% | -65.99% | -60.23% | -32.98% | -9.22% |
| Total Other Non-Cash Items | -229.22% | -177.15% | -121.58% | -92.29% | -11.00% |
| Change in Net Operating Assets | -135.97% | -80.37% | -142.16% | -101.22% | 29.05% |
| Cash from Operations | 44.86% | 53.53% | 49.59% | 34.33% | 22.49% |
| Capital Expenditure | -- | -- | 100.00% | 100.00% | -5.26% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 100.00% | 100.00% | -5.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -8.23% | 44.11% | 39.05% | 36.94% | 16.55% |
| Repurchase of Common Stock | -- | -100.00% | 70.37% | 70.37% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -214.36% | 52.17% | 25.98% | 27.88% | 89.10% |
| Cash from Financing | -19.87% | 38.22% | 41.14% | -37.51% | -75.91% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 52.80% | 72.48% | 65.18% | 32.70% | -161.73% |